Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: The J-CORE study

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 184-188

  Matsui, Yoshio ^a   Eguchi, Kazuo ^a   O'Rourke, Michael F ^b   Ishikawa, Joji ^a   Shimada, Kazuyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Aldosterone; Aortic pulse wave velocity; Calcium channel blocker; Mean arterial pressure; Thiazide diuretic

Indexed keywords

ALDOSTERONE; AZELNIDIPINE; HYDROCHLOROTHIAZIDE; OLMESARTAN;

ADD ON THERAPY; AGED; ALDOSTERONE BLOOD LEVEL; AORTA; ARTERIAL STIFFNESS; ARTICLE; CAROTID ARTERY; CLINICAL TRIAL; FEMALE; FEMORAL ARTERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZATION; SINGLE BLIND PROCEDURE;

AGED; ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; AORTA; AZETIDINECARBOXYLIC ACID; BLOOD FLOW VELOCITY; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; IMIDAZOLES; MALE; PULSATILE FLOW; TETRAZOLES; VASCULAR RESISTANCE;

EID: 79952102598     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.022     Document Type: Article

References (30)

1. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 55:1318-1327.
2. Guerin A.P., Blacher J., Pannier B., et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001, 103:987-992.
3. Mahmud A., Feely J. Arterial stiffness and the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2004, 5:102-108.
4. Leibovitz E., Ebrahimian T., Paradis P., Schiffrin E.L. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens 2009, 27:2192-2200.
5. Park S., Kim J.B., Shim C.Y., et al. The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients. J Hypertens 2007, 25:1279-1283.
6. Lieb W., Larson M.G., Benjamin E.J., et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham heart study. Circulation 2009, 119:37-43.
7. Asmar R.G., Benetos A., Chaouche-Teyara K., Raveau-Landon C.M., Safar M.E. Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. Am J Cardiol 1993, 72:794-798.
8. Ishimitsu T., Numabe A., Masuda T., et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009, 32:962-968.
9. Matsui Y., Eguchi K., O'Rourke M.F., et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009, 54:716-723.
10. Kool M.J., Lustermans F.A., Breed J.G., et al. The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens 1995, 13:839-848.
11. Bénétos A., Laflèche A., Asmar R., et al. Arterial stiffness, hydrochlorothiazide and converting enzyme inhibition in essential hypertension. J Hum Hypertens 1996, 10:77-82.
12. Mahmud A., Feely J. Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002, 15:1092-1095.
13. Mahmud A., Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005, 18:50-55.
14. Vogt L., Waanders F., Boomsma F., de Zeeuw D., Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19:999-1007.
15. Safar M.E., Thuilliez C., Richard V., Benetos A. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res 2000, 46:269-276.
16. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American heart association council on high blood pressure research. Hypertension 2005, 45:142-161.
17. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
18. Safar M.E. Can antihypertensive treatment reverse large-artery stiffening?. Curr Hypertens Rep 2010, 12:47-51.
19. Simon G., Jaeckel M., Illyes G. Altered structure and distensibility of arteries in salt-fed rats. J Hypertens 2003, 21:137-143.
20. Gates P.E., Tanaka H., Hiatt W.R., Seals D.R. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004, 44:35-41.
21. Lacolley P., Labat C., Pujol A., et al. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002, 106:2848-2853.
22. Lombès M., Oblin M.E., Gasc J.M., et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992, 71:503-510.
23. Eguchi K., Tomizawa H., Ishikawa J., et al. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. J Cardiovasc Pharmacol 2007, 49:394-400.
24. Kondo T., Goto R., Sonoda K., et al. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients. Intern Med 2010, 49:637-643.
25. Veglio F., Molino P., Cat Genova G., et al. Impaired baroreflex function and arterial compliance in primary aldosteronism. J Hum Hypertens 1999, 13:29-36.
26. Strauch B., Petrák O., Wichterle D., et al. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006, 19:909-914.
27. Duprez D.A. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich) 2007, 9:13-18.
28. Schmidt B.M., Oehmer S., Delles C., et al. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003, 42:156-160.
29. Kontak A.C., Wang Z., Arbique D., et al. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab 2010, 95:4756-4761.
30. Savoia C., Touyz R.M., Amiri F., Schiffrin E.L. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008, 51:432-439.